预约演示
更新于：2025-02-06
Taltirelin Hydrate
他替瑞林水合物
更新于：2025-02-06
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2000-09-21), |
最高研发阶段(中国)- |
特殊审评孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C17H31N7O9 |
InChIKeyHRCJDWMUKPHPHR-NTFWNTCYSA-N |
CAS号201677-75-0 |
关联
4
项与 他替瑞林水合物 相关的临床试验CTR20233554
评价他替瑞林片在中国成年健康受试者中的一项单中心、随机、开放、空腹/餐后单次给药、两制剂、两周期、双交叉的生物等效性研究
CTR20232774
他替瑞林片随机、开放、两制剂、两周期、双交叉在健康人体餐后条件下生物等效性试验
CTR20232775
他替瑞林片随机、开放、两制剂、两周期、双交叉在健康人体空腹条件下生物等效性试验
100 项与 他替瑞林水合物 相关的临床结果
登录后查看更多信息
100 项与 他替瑞林水合物 相关的转化医学
登录后查看更多信息
100 项与 他替瑞林水合物 相关的专利（医药）
登录后查看更多信息
133
项与 他替瑞林水合物 相关的文献（医药）2025-01-31Journal of Movement Disorders
Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
Article
作者: Lyoo, Chul Hyoung ; Kim, Han-Joon ; Cho, Jin Whan ; Koh, Seong-Beom ; Choi, Seong-Min ; Kim, Joong-Seok ; Park, Kun-Woo ; Lee, Jee-Young
Objective We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).Methods Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.Results A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).Conclusion Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
2024-11-27BIOLOGICAL & PHARMACEUTICAL BULLETIN
Thyrotropin-Releasing Hormone Analog Taltirelin Inhibits Acute and Chronic Itch in Mice
Article
作者: Kojima, Fumiaki ; Ogata, Masanori ; Eto, Kei ; Ishibashi, Hitoshi
Itch is an unpleasant sensation that induces a desire to scratch. Chronic itch is accompanied by inflammatory skin diseases and causes repetitive scratching leading to tissue damage. The thyrotropin-releasing hormone analog taltirelin exerts analgesic effects on acute and chronic pain by activating the descending inhibitory systems. However, little is known regarding its effects on acute and chronic itch. In this study, we examined the effects of taltirelin on acute and chronic itch. Subcutaneous injection of chloroquine increased the number of scratching bouts in 30 min, whereas intraperitoneal injection of taltirelin reduced these episodes in a dose-dependent manner. In addition, chronic itch induced by diphenylcyclopropenone treatment was alleviated by taltirelin injection. These findings indicate that taltirelin alleviates acute and chronic itch in mice, and can be a potent therapeutic antipruritic drug.
2024-09-20Cureus Journal of Medical Science
Multiple System Atrophy Masquerading as Drug-Resistant Orthostatic Hypotension
Article
作者: Sasaki, Kenta ; Yamaoka, Manami ; Neshige, Shuichiro ; Maruyama, Hirofumi
A 54-year-old male presented with a two-year history of recurrent syncope. Although he was treated with droxidopa and amezinium metilsulfate, his syncope was drug-resistant. Blood tests, cardiac evaluation and brain computed tomography (CT) were unremarkable. As his Schellong test was positive, orthostatic hypotension and syncope were the tentative diagnoses. Upon evaluating the patient neurologically while carefully avoiding syncope induction, mild cerebellar ataxia was observed. However, a brain magnetic resonance imaging (MRI) scan revealed a possible "cross sign" in the pons. Subsequent dopamine transporter single-photon emission computed tomography (DAT-SPECT) showed reduced uptake in the basal ganglia. Based on these findings, a clinical diagnosis of probable multiple system atrophy of the cerebellar type (MSA-C) was made, and treatment with taltirelin hydrate was initiated. This case underscores the importance of considering multiple system atrophy (MSA) in patients with persistent orthostatic hypotension and syncope, even before more obvious neurodegenerative symptoms emerge.
100 项与 他替瑞林水合物 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脊髓小脑变性 | 日本 | 2009-10-26 | |
| 神经系统疾病 | 日本 | 2000-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中枢神经系统疾病 | 临床前 | 日本 | 2002-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用